SEC Form 4 · accession 0001209191-16-095962
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Feb 3, 2016
Accepted (ET)
Feb 5, 2016 · 3:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 3, 2016 | M | 5,130 | $35.35 | A | 270,414 | D | |
| Common StockF2,F3 | Feb 3, 2016 | S | 200 | $86.66 | D | 270,214 | D | |
| Common StockF3,F4 | Feb 3, 2016 | S | 500 | $88.11 | D | 269,714 | D | |
| Common StockF3,F5 | Feb 3, 2016 | S | 1,100 | $89.60 | D | 268,614 | D | |
| Common StockF3,F6 | Feb 3, 2016 | S | 1,300 | $90.63 | D | 267,314 | D | |
| Common StockF3,F7 | Feb 3, 2016 | S | 700 | $91.58 | D | 266,614 | D | |
| Common StockF3,F8 | Feb 3, 2016 | S | 800 | $92.94 | D | 265,814 | D | |
| Common StockF3,F9 | Feb 3, 2016 | S | 530 | $93.61 | D | 265,284 | D | |
| Common Stock | holding | — | — | — | 13,286 | I | 401k | |
| Common Stock | holding | — | — | — | 122,700 | I | Common Stock Held In Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F10 | $35.35 | Feb 3, 2016 | M | 5,130 | D | — | Jul 19, 2016 | Common Stock | 5,130 | 112,870 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- F10Fully vested.
- F2Open market sales reported on this line occurred at a weighted average price of $86.66 (range $86.37 to $86.94).
- F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $88.11(range $87.82 to $88.30).
- F5Open market sales reported on this line occurred at a weighted average price of $89.60 (range $89.15 to $90.08).
- F6Open market sales reported on this line occurred at a weighted average price of $90.63 (range $90.20 to $91.07).
- F7Open market sales reported on this line occurred at a weighted average price of $91.58 (range $91.25 to $92.22).
- F8Open market sales reported on this line occurred at a weighted average price of $92.94 (range $92.32 to $93.15).
- F9Open market sales reported on this line occurred at a weighted average price of $93.61 (range $93.34 to $93.96).